Stanford Medicine‘s history in cancer immunotherapy dates back to the 1980s – from researching personalized anticancer antibodies to treating pediatric leukemia with T-cells. More recently, Stanford scientists created a host of tools essential to new immunotherapy treatments. They shed light on T-cells, giving scientists a fresh look at the immune system through single-cell analysis and enable the mapping of regulatory DNA. This technology is being used across our research platform, driving PICI research forward. Crystal Mackall, MD | Director Mark Davis, PhD | Co-Director Ansuman Satpathy, MD, PhD | Co-Director All Investigators Related Research Update Where Cancer-killing T-cells Come From Announcement PICI Young Investigator Retreat 2019 Research Update Predicting Childhood Leukemia Relapse Using Machine Learning Announcement, Our Impact PICI-Founded Dispatch Bio Takes on Solid Tumors Announcement CNBC Honors Dr. Karen Knudsen, PICI CEO, as Changemaker Research Update Data to Design: Inside Our Spring Scientific Retreat Announcement, Our Impact, Press Release PICI at ASCO: New Data. Big Impact. Top Honors. Announcement, Partner Highlight, Press Release New PICI Collaboration Bolsters Science-to-Market Edge Announcement, Partner Highlight, Press Release PICI, Immunai to Build Landmark Cancer Dataset
Announcement, Partner Highlight, Press Release New PICI Collaboration Bolsters Science-to-Market Edge